RNA-Based Therapy Aims to Enhance Heart Regeneration Post-Heart Attack

A new RNA-based therapy developed by researchers at Columbia University seeks to address a significant challenge in cardiology: the heart's limited ability to regenerate after injury, particularly following a heart attack. After such events, although blood flow can be restored, permanent damage often remains due to the loss of muscle cells that do not regenerate. Ke Cheng, the Alan L. Kaganov Professor of Biomedical Engineering, emphasized the heart's minimal spontaneous regeneration capabilities, which contribute to the high incidence of heart failure among survivors. The experimental therapy aims not only to prevent further damage but also to actively promote the heart's self-repair mechanisms.

SciTechDaily

The innovative therapy utilizes RNA to instruct other tissues in the body to produce a healing molecule that activates specifically within the heart. This method eliminates the need for invasive procedures, as the treatment can be administered via a simple injection into the arm. In preclinical studies, a single injection significantly reduced scar tissue and improved heart function in both small and large animal models. The therapy leverages the body's natural processes, drawing inspiration from the regenerative capabilities observed in newborns, where a hormone called atrial natriuretic peptide (ANP) plays a crucial role in promoting heart muscle regeneration.

SciTechDaily

In their studies, researchers found that the gene responsible for producing ANP's precursor, known as Nppa, increased significantly more in newborn mice than in adults, indicating a potential reason for the regenerative differences. The therapy involves a two-step process where RNA-lipid nanoparticles are injected into skeletal muscle, prompting the production of pro-ANP, which is then activated by an enzyme called Corin in the heart. This method ensures targeted delivery of the healing molecule, with effects lasting for at least four weeks post-injection.

SciTechDaily

Looking ahead, Cheng's team plans to conduct human trials following successful preclinical testing across various conditions, including older mice and those with comorbidities like atherosclerosis and type 2 diabetes. The researchers aim to demonstrate the therapy's effectiveness even when administered after significant heart damage has occurred. Beyond heart disease, this approach holds promise for treating other conditions such as kidney disease and high blood pressure, potentially revolutionizing regenerative medicine across multiple organ systems.

SciTechDaily

Cheng expressed optimism about the therapy's potential, stating, “We hope that, even if a patient had a heart attack weeks before getting the drug, it’s still effective.” Torsten Vahl, a co-author of the study, highlighted the unmet need for effective treatments in cardiology, noting that many patients are left with severe heart damage post-heart attack.

SciTechDaily

While the therapy shows promise, it is essential to await results from human trials to fully assess its safety and efficacy. Critics may point to the challenges of translating animal model results to human applications, emphasizing the need for rigorous testing before widespread clinical use.

SciTechDaily

• “The heart is one of the organs with the least ability to regenerate,” — Ke Cheng, Alan L. Kaganov Professor of Biomedical Engineering

SciTechDaily

• “As a clinician who opens up arteries with stents for patients who come to us with heart attacks, I am highly aware that we have a large unmet need for our patients,” — Torsten Vahl, Co-Author

SciTechDaily

This innovative RNA-based therapy represents a significant advancement in cardiac care, with the potential to transform treatment paradigms for heart attack survivors and beyond.

SciTechDaily